-

Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies, today announced that Adam Rosenthal, Ph.D., CEO and Founder, will present a company overview at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11th at 10:30 a.m. PT. The conference is being held in San Francisco from January 8-11, 2024.

About Star Therapeutics

Star Therapeutics is a biotechnology company that interrogates areas of novel biology to develop life-changing therapies for as many patients as possible, initially addressing unmet needs in hematology and immunology. The company’s engine for innovation starts with identifying multiple diseases that share a common biology and then discovering novel therapeutics that can treat numerous diseases with a single therapy. Star consists of a constellation of companies, each focused on a specific area of biology with first-in-class therapies. Star is backed by leading life sciences investors and located in South San Francisco. For more information, please visit www.star-therapeutics.com and follow us on LinkedIn.

Contacts

Media
Kathryn Morris, The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com

Industry:

Star Therapeutics

Details
Employees: undefined
Release Versions
English

Contacts

Media
Kathryn Morris, The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com

Social Media Profiles
Star Therapeutics/LinkedIn
Star Therapeutics/Twitter
More News From Star Therapeutics

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VGA039 in von Willebrand disease (VWD). VGA039 is an investigational monoclonal antibody that targets Protein S to restore balance in blood clotting, as a universal hemostatic therapy for numerous bleeding disorders. It is potentially the...

Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced that it will present at the 43rd annual J.P. Morgan Healthcare Conference taking place on January 13-16, 2025 in San Francisco, CA. Adam Rosenthal, Ph.D., CEO and Founder of Star Therapeutics, is scheduled to present an overview of the company and its lead drug candidate, VGA039, a therapy for von Willebrand disease (VWD) an...

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced interim clinical data from VIVID 2 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 single ascending dose (SAD) study of VGA039 in Von Willebrand Disease (VWD) patients. VGA039 is an investigational monoclonal antibody that targets Protein S to restore balance in blood clotting, as a universal hemostatic therapy f...
Back to Newsroom